

At a Glance

In the business domains of “food and well-being,” the Kirin Group conducts business activities on a global basis, centered on alcoholic beverages, non-alcoholic beverages, and pharmaceuticals and bio-chemicals. In this way, the Group is taking on the challenge of “creating new value.”

Japan Integrated Beverages

Fiscal 2016 results

Sales

¥1,153.2 billion

Composition of sales

56%


Operating income

¥67.2 billion

Assets

¥821.6 billion

Results for the Last Five Years



Principal Companies

- Kirin Company
- Kirin Brewery
- Kirin Beverage
- Mercian

Overseas Integrated Beverages

Fiscal 2016 results

Sales

¥561.4 billion

Composition of sales


27%

Operating income

¥43.3 billion

Assets

¥932.7 billion



- Lion
- Brasil Kirin
- Myanmar Brewery*

* Profit and loss has been consolidated from fiscal 2016.

Pharmaceuticals and Bio-chemicals

Fiscal 2016 results

Sales

¥335.7 billion

Composition of sales


16%

Operating income

¥34.7 billion

Assets

¥720.7 billion



- Kyowa Hakko Kirin
- Kyowa Hakko Bio

Description of Business

The Japan Integrated Beverages Business conducts manufacturing and sales of alcoholic beverages and non-alcoholic beverages in Japan, centered on Kirin Brewery, Kirin Beverage, and Mercian. Kirin Company, the regional headquarters, works to strengthen the core brands through the allocation of management resources in a manner that transcends the alcoholic and non-alcoholic beverage framework. Moreover, Kirin Company strives to create value that leads to surprise and inspiration by offering exceptional quality and taste while addressing societal issues from the perspective of the customer's well-being and link to society, based on the brand message "Quality with Surprise."

The Japan Integrated Beverages Business also works to expand sales of Kirin brand products in Asia, Europe, the United States, and other regions.

Major Products



Leveraging the companies acquired through aggressive internationalization measures as its operating foundation, the Kirin Group manufactures and sells alcoholic and non-alcoholic beverages on a global basis. The operating companies implement management in an autonomous manner for the most part, but at the same time the holding company, Kirin Holdings, actively works together with the operating companies to develop and implement strategies, and to resolve issues in order to maximize the operating companies' growth potential.

In addition, with New KV2021 as a shared vision and strategic framework, the overseas operating companies draw on each other's strengths as well as the technical expertise cultivated in Japan, thereby supporting the growth of the Group as a whole.



Kyowa Hakko Kirin, which is responsible for the current Pharmaceuticals and Bio-chemicals Businesses, was created through the merger in 2008 of Kyowa Hakko Kogyo and Kirin Pharma, which handled the Kirin Group's pharmaceutical operations.

In the pharmaceuticals business, Kyowa Hakko Kirin conducts development, manufacturing, and sales of ethical drugs based on leading-edge biotechnology. In the bio-chemicals business, the company leverages innovative fermentation and synthesis technologies to provide high-value functional materials that meet a variety of needs in the pharmaceutical, medical, and healthcare fields.

